Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer

This publication has 22 references indexed in Scilit:

• Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
  Journal of Clinical Oncology, 1997
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
  Journal of Clinical Oncology, 1994
• Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
  Journal of Clinical Oncology, 1993
• CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative
  European Journal Of Cancer, 1992
• Effects of CPT‐11 in combination with other anti‐cancer agents in culture
  International Journal of Cancer, 1992
• A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.
  Proceedings of the National Academy of Sciences, 1989
• Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme.
  Proceedings of the National Academy of Sciences, 1976